Frontiers in glioblastoma therapy: Novel therapeutics, molecular pathways, and future clinical perspectives

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Human Gene

• Publication date

  2025-11-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.humgen.2025.201507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system

  2025cited by this paper
• Surgical efficacy and survival outcomes of fluorescein sodium-guided surgery in glioblastoma: a single-center experience

  2025cited by this paper
• Localized treatment of glioblastoma: a review of clinical strategies and advances in drug delivery systems

  2025cited by this paper
• The Pivotal Role of NF-κB in Glioblastoma: Mechanisms of Activation and Therapeutic Implications

  2025cited by this paper
• Progenitor cells, microglia, and non-coding RNAs: Orchestrators of glioblastoma pathogenesis and therapeutic resistance

  2025cited by this paper
• Proteomic Analysis Uncovers Enhanced Inflammatory Phenotype and Distinct Metabolic Changes in IDH1 Mutant Glioma Cells

  2025cited by this paper
• Glioblastoma metabolomics: uncovering biomarkers for diagnosis, prognosis and targeted therapy

  2025cited by this paper
• HADHA-mediated regulation of JAK/STAT3 signaling in glioblastoma: a metabolic-epigenetic axis

  2025cited by this paper
• DNA methylation remodeling in temozolomide resistant recurrent glioblastoma: comparing epigenetic dynamics in vitro and in vivo

  2025cited by this paper
• Glioblastoma at the crossroads: current understanding and future therapeutic horizons

  2025cited by this paper
• Impact of extent of surgical resection on survival in World Health Organization grade 4 gliomas: A molecular subtype-based analysis

  2025cited by this paper
• XPO1-inhibitor Selinexor induces MGMT expression by activating PKA-CREB signaling in IDH wildtype glioblastoma

  2025cited by this paper
• Noninvasive Computed Tomography-Based Quantification of Tumor Fibrosis Predicts Pancreatic Cancer Response to Gemcitabine/Nab-Paclitaxel

  2025cited by this paper
• In vivo chimeric antigen receptor (CAR)-T cell therapy

  2025cited by this paper
• Current Applications and Technical Considerations of Indocyanine Green during Endonasal Endoscopic Approaches for Resection of Pituitary Region Tumors: A Systematic Review.

  2025cited by this paper
• A Self-Homing Liposomal Nanobot for Active Therapy of Glioblastoma.

  2025cited by this paper
• EGFRvIII-positive glioblastoma contributes to immune escape and malignant progression via the c-Fos-MDK-LRP1 axis

  2025cited by this paper
• Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study.

  2025cited by this paper
• Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights

  2025cited by this paper
• Fluorescence-Guided Surgery for Gliomas: Past, Present, and Future

  2025cited by this paper
• Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines

  2025cited by this paper
• IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study

  2025cited by this paper
• Targeting the glioblastoma resection margin with locoregional nanotechnologies

  2025cited by this paper
• Comparative Analysis of 5-ALA and Fluorescent Techniques in High-Grade Glioma Treatment

  2025cited by this paper
• A systematic review and meta-analysis of deep learning and radiomics in predicting MGMT promoter methylation status in glioblastoma: Efficacy, reliability, and clinical implications

  2025cited by this paper
• EGFR transcript variants: Potential diagnostic biomarker for glioblastoma, IDH-wildtype?

  2025cited by this paper
• Magnetic resonance spectroscopy guided radiotherapy boost for patients with glioblastoma

  2025cited by this paper
• Multi-transcriptomics reveals niche-specific expression programs and endothelial cells in glioblastoma

  2025cited by this paper
• Tumor Treating Fields and Combination Therapy in Management of Brain Oncology

  2025cited by this paper
• Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions

  2025cited by this paper
• Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade

  2025cited by this paper
• Suppression of FOXO1 activity by SIRT1-mediated deacetylation weakening the intratumoral androgen autocrine function in glioblastoma

  2025cited by this paper
• Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience

  2025cited by this paper
• Awake craniotomy versus general anesthesia for resection of intra-axial brain tumors: A systematic review and meta-analysis

  2025cited by this paper
• Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies

  2025cited by this paper
• Raman Spectroscopy in the Diagnosis of Brain Gliomas: A Literature Review

  2025cited by this paper
• Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment

  2025cited by this paper
• Associated adverse outcomes with tumor treating fields when combined to temozolomide versus temozolomide alone for the treatment of glioblastoma: a meta-analysis of randomized trials

  2025cited by this paper
• Translational nanorobotics breaking through biological membranes.

  2025cited by this paper
• Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes

  2025cited by this paper
• Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review

  2024cited by this paper
• Liquid biopsy in cancer management: Integrating diagnostics and clinical applications

  2024cited by this paper
• Addressing the role of surgery in brain tumour trials: A report from the neurosurgery committee of the EORTC brain tumour group.

  2024cited by this paper
• Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results

  2024cited by this paper
• Nanorobots mediated drug delivery for brain cancer active targeting and controllable therapeutics

  2024cited by this paper
• DDDR-35. THERAPEUTIC STRATEGIES FOR DIFFUSE MIDLINE GLIOMA: INSIGHTS FROM HIGH-THROUGHPUT COMBINATION DRUG AND RADIATION SENSITIZATION SCREENING

  2024cited by this paper
• The Clinical Significance of Viral Vulnerability and Iron Overload in T-cell Acute Lymphoblastic Leukemia

  2024cited by this paper
• Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma

  2024cited by this paper
• EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma

  2024cited by this paper
• Updates for newly diagnosed and recurrent glioblastoma: a review of recent clinical trials

  2024cited by this paper
• Glioblastoma cells increase expression of notch signaling and synaptic genes within infiltrated brain tissue

  2024cited by this paper
• Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma

  2024cited by this paper
• Cost-effectiveness analysis of bevacizumab combined with lomustine in the treatment of progressive glioblastoma using a Markov model simulation analysis

  2024cited by this paper
• An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery

  2024cited by this paper
• Association of 5-aminolevulinic acid fluorescence guided resection with photodynamic therapy in recurrent glioblastoma: a matched cohort study

  2024cited by this paper
• Regulation of Hypoxia Dependent Reprogramming of Cancer Metabolism: Role of HIF-1 and Its Potential Therapeutic Implications in Leukemia

  2024cited by this paper
• Tumor treating fields in glioblastoma: long-term treatment and high compliance as favorable prognostic factors

  2024cited by this paper
• Molecular GBM versus Histopathological GBM: Radiology-Pathology-Genetic Correlation and the New WHO 2021 Definition of Glioblastoma

  2024cited by this paper
• HIF1α/ATF3 partake PGK1 K191/K192 succinylation by modulating P4HA1/succinate signaling in glioblastoma.

  2024cited by this paper
• Targeting Wnt signaling for improved glioma immunotherapy

  2024cited by this paper
• Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3.

  2024cited by this paper
• Expression of CXCL8 (IL-8) in the Pathogenesis of T-Cell Acute Lymphoblastic Leukemia Patients

  2023cited by this paper
• Nanoparticle-Based Treatment in Glioblastoma

  2023cited by this paper
• Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis

  2023cited by this paper
• Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma

  2023cited by this paper
• Glioma-associated microglia/macrophages (GAMs) in glioblastoma: Immune function in the tumor microenvironment and implications for immunotherapy

  2023cited by this paper
• Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives

  2023cited by this paper
• JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens

  2023cited by this paper
• Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment

  2023cited by this paper
• Key Clinical Principles in the Management of Glioblastoma.

  2023cited by this paper
• The FOXO1 inhibitor AS1842856 triggers apoptosis in glioblastoma multiforme and basal‐like breast cancer cells

  2023cited by this paper
• Hypoxia-induced one-carbon metabolic reprogramming in glioma stem-like cells

  2023cited by this paper
• JAK3 Inhibition Regulates Stemness and Thereby Controls Glioblastoma Pathogenesis

  2023cited by this paper
• The semaphorin 3A/neuropilin-1 pathway promotes clonogenic growth of glioblastoma via activation of TGF-β signaling

  2023cited by this paper
• Emerging therapies for glioblastoma: current state and future directions

  2022cited by this paper
• EGFR Amplification Is a Phenomenon of IDH Wildtype and TERT Mutated High-Grade Glioma: An Integrated Analysis Using Fluorescence In Situ Hybridization and DNA Methylome Profiling

  2022cited by this paper
• Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy

  2022cited by this paper
• Fluorescence-Guided Surgery in Glioblastoma: 5-ALA, SF or Both? Differences between Fluorescent Dyes in 99 Consecutive Cases

  2022cited by this paper
• Progress and Viewpoints of Multifunctional Composite Nanomaterials for Glioblastoma Theranostics

  2022cited by this paper
• ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449

  2022cited by this paper
• Optimization of Tumor Targeting Gold Nanoparticles for Glioblastoma Applications

  2022cited by this paper
• Natural killer cell immunotherapy in glioblastoma

  2022cited by this paper
• Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma

  2022cited by this paper
• Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

  2022cited by this paper
• Idylla EGFR assay on extracted DNA: advantages, limits and place in molecular screening according to the latest guidelines for non-small-cell lung cancer (NSCLC) patients

  2022cited by this paper
• Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors.

  2022cited by this paper
• Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives

  2022cited by this paper
• Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma

  2022cited by this paper
• Is Interstitial Chemotherapy with Carmustine (BCNU) Wafers Effective against Local Recurrence of Glioblastoma? A Pharmacokinetic Study by Measurement of BCNU in the Tumor Resection Cavity

  2022cited by this paper
• Glioblastoma Stem Cells—Useful Tools in the Battle against Cancer

  2022cited by this paper
• Endothelial β-Catenin Deficiency Causes Blood-Brain Barrier Breakdown via Enhancing the Paracellular and Transcellular Permeability

  2022cited by this paper
• Targeting Mitochondrial Oxidative Phosphorylation in Glioblastoma Therapy

  2021cited by this paper
• Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery

  2021cited by this paper
• Exosome-mediated delivery of RNA and DNA for gene therapy.

  2021cited by this paper
• NIK promotes metabolic adaptation of glioblastoma cells to bioenergetic stress

  2021cited by this paper
• Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives

  2021cited by this paper
• Novel therapies emerging in oncology to target the TGF-β pathway

  2021cited by this paper
• From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas

  2021cited by this paper
• Let Me See: Correlation between 5-ALA Fluorescence and Molecular Pathways in Glioblastoma: A Single Center Experience

  2021cited by this paper
• The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

  2021cited by this paper

• Decoding myeloid heterogeneity in glioblastoma: spatial insights from transcriptomics.

  2026cites this paper